Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. - Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson ML; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025)